Prestige BioPharma report positive top-line phase III results for Tuznue

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Prestige BioPharma announced positive top-line results from a phase III global clinical trial (Troika) evaluating the efficacy, safety, and pharmacokinetics of biosimilar candidate HD201 to Herceptin (trastuzumab).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

When Olufunmilayo I. “Funmi” Olopade was born, the most common Nigerian career aspirations were pastor or teacher. Olopade’s father, a pastor, thought differently. He wanted his children to be scientists, economists, and doctors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login